Thyrocare Technologies (NSE:THYROCARE) Altman Z2-Score: 8.64 (As of Jul. 13, 2026) — 13% Below Median


NSE:THYROCARE Thyrocare Technologies Ltd NSE:THYROCARE
89 GF Score
Price ₹515.70
GF Value ₹395.22
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Thyrocare Technologies Altman Z2-Score?

Thyrocare Technologies NSE:THYROCARE -3.71% 89 Altman Z2-Score is 8.64 as of Jul. 13, 2026, which is 13% below its 10-year median of 9.93. GuruFocus rates NSE:THYROCARE with a GF Score™ of 89/100 and a GF Value™ of ₹395.22 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 84.76% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Thyrocare Technologies has a Altman Z2-Score of 8.64, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Thyrocare Technologies's Altman Z2-Score or its related term are showing as below:

NSE:THYROCARE' s Altman Z2-Score Range Over the Past 10 Years
Min: 8.11   Med: 9.93   Max: 18.91
Current: 8.64

During the past 13 years, Thyrocare Technologies's highest Altman Z2-Score was 18.91. The lowest was 8.11. And the median was 9.93.


Thyrocare Technologies  (NSE:THYROCARE) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Thyrocare Technologies Altman Z2-Score Related Terms


Thyrocare Technologies Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Thyrocare Technologies's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thyrocare Technologies Altman Z2-Score Chart

Thyrocare Technologies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.50 10.52 9.34 8.91 8.64

Thyrocare Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.91 0.00 7.67 0.00 8.64

NSE:THYROCARE vs TMO, DHR, IDXX: Altman Z2-Score Comparison

For the Diagnostics & Research subindustry, Thyrocare Technologies's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thyrocare Technologies Altman Z2-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Thyrocare Technologies's Altman Z2-Score falls into.


NSE:THYROCARE
89GF Score
Thyrocare Technologies Ltd NSE:THYROCARE
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thyrocare Technologies Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Thyrocare Technologies's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.3511+3.26*0.1785+6.72*0.2886+1.05*3.6321
=8.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was ₹7,472 Mil.
Total Current Assets was ₹3,723 Mil.
Total Current Liabilities was ₹1,099 Mil.
Retained Earnings was ₹1,334 Mil.
Pre-Tax Income was 644.3 + 353.9 + 625.8 + 504.8 = ₹2,129 Mil.
Interest Expense was -15.2 + 0.9 + -5.9 + -7.8 = ₹-28 Mil.
Total Liabilities was ₹1,612 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(3722.9 - 1099.1)/7472.2
=0.3511

X2=Retained Earnings/Total Assets
=1333.9/7472.2
=0.1785

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(2128.8 - -28)/7472.2
=0.2886

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(5855 - 0)/1612
=3.6321

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Thyrocare Technologies has a Altman Z2-Score of 8.64 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 8.64 mean?
Thyrocare Technologies (NSE:THYROCARE) has a Altman Z2-Score of 8.64 as of Jul. 13, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Thyrocare Technologies and its competitors. This is 13% below median its historical median of 9.93. Over the past decade, Thyrocare Technologies' Altman Z2-Score has ranged from 8.11 to 18.91. According to the industry distribution chart, Thyrocare Technologies ranks #32 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 15.2%.
Is Thyrocare Technologies' Altman Z2-Score too high?
Thyrocare Technologies' current Altman Z2-Score of 8.64 is 13% below median its 10-year median of 9.93. Over the past 10 years, this metric has ranged from a low of 8.11 to a high of 18.91. The Medical Diagnostics & Research industry median Altman Z2-Score is 1.99. Thyrocare Technologies' value of 8.64 is 334.2% above this industry median. Based on the distribution chart, Thyrocare Technologies ranks #32 out of 210 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Altman Z2-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #32 out of 210 companies for Altman Z2-Score. This places Thyrocare Technologies in the top 15% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 1.99. Thyrocare Technologies' value of 8.64 is 334.2% above this benchmark. Historically, Thyrocare Technologies' own Altman Z2-Score has ranged from 8.11 to 18.91 over the past decade. While the company's 10-year median is 9.93 vs. the industry median of 1.99, Thyrocare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Diagnostics & Research company?
The median Altman Z2-Score among Medical Diagnostics & Research companies is 1.99, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thyrocare Technologies's current Altman Z2-Score of 8.64 is 334.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Thyrocare Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z2-Score is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current Altman Z2-Score is 8.64, which is 13% below median its own 10-year median of 9.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹395.22, compared to a current price of ₹515.70 — trading 30.5% above its estimated fair value. The current Altman Z2-Score is 8.64, which is 13% below median its 10-year median of 9.93 and 334.2% above the Medical Diagnostics & Research industry median of 1.99. Thyrocare Technologies' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Altman Z2-Score is 8.64 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?

Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued. The current stock price of ₹515.70 is trading 30.5% above its estimated GF Value™ of ₹395.22. GuruFocus considers Thyrocare Technologies to be Modestly Overvalued.

Key valuation signals for NSE:THYROCARE:

  • Altman Z2-Score: 8.64 (13% below median its 10-year median of 9.93)
  • GF Value™: ₹395.22 vs. price of ₹515.70 (30.5% above fair value)
  • GF Score™: 89/100 with 5 warning signs
  • Industry Position: 334.2% above the Medical Diagnostics & Research median (#32 of 210)

No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Thyrocare Technologies Business Description

Other Exchanges 539871:India
Address D-37/3, TTC Industrial Area, MIDC, Turbhe, Opposite Sandoz, Navi Mumbai, MH, IND, 400703
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
89GF Score

Get the complete analysis for NSE:THYROCARE

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹515.70
Price
₹395.22
GF Value